Evotec announced that it has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb originally signed in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for additional 8 years with the goal to further broaden and deepen the strategic alliance.
Evotec and Bristol Myers Squibb initiated the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. This partnership pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec
